{"id":"tp-regimen","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Neutropenia"},{"rate":"20-40","effect":"Anemia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"30-50","effect":"Nausea and vomiting"},{"rate":"10-30","effect":"Peripheral neuropathy"},{"rate":"5-15","effect":"Nephrotoxicity"},{"rate":"50-80","effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The TP regimen combines two cytotoxic agents: docetaxel, a taxane that stabilizes microtubules and prevents cell division, and cisplatin, a platinum-based alkylating agent that cross-links DNA and induces apoptosis. This combination targets rapidly dividing cancer cells through complementary mechanisms, enhancing overall cytotoxic effect compared to single-agent therapy.","oneSentence":"TP regimen is a chemotherapy combination of docetaxel (Taxotere) and cisplatin that disrupts microtubule dynamics and DNA replication to kill cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:39:33.257Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Gastric cancer"},{"name":"Head and neck cancer"},{"name":"Breast cancer"}]},"trialDetails":[{"nctId":"NCT06535607","phase":"PHASE2","title":"Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-22","conditions":"Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)","enrollment":257},{"nctId":"NCT06244303","phase":"PHASE3","title":"Clinical Research Study to Assess the Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and Gingivitis.","status":"COMPLETED","sponsor":"Colgate Palmolive","startDate":"2024-01-22","conditions":"Gingivitis, Plaque","enrollment":82},{"nctId":"NCT07479628","phase":"PHASE2","title":"Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2026-04-01","conditions":"Thymic Carcinoma","enrollment":31},{"nctId":"NCT07362979","phase":"PHASE2","title":"Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-12","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":243},{"nctId":"NCT07471815","phase":"PHASE2","title":"Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harbin Medical University","startDate":"2026-03-04","conditions":"Breast Cancer Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT05378334","phase":"NA","title":"Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients","status":"RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2022-06-15","conditions":"Non-small Cell Lung Cancer","enrollment":82},{"nctId":"NCT07331155","phase":"PHASE2","title":"A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2026-02-26","conditions":"Advanced Solid Tumour","enrollment":110},{"nctId":"NCT05247684","phase":"PHASE2","title":"AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-02-20","conditions":"Resectable Non-small Cell Lung Cancer","enrollment":90},{"nctId":"NCT07039162","phase":"PHASE2","title":"Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Ming-Yu Lien","startDate":"2025-09-26","conditions":"Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer","enrollment":45},{"nctId":"NCT03774732","phase":"PHASE3","title":"PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2018-01-24","conditions":"Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4","enrollment":327},{"nctId":"NCT04605913","phase":"PHASE1, PHASE2","title":"Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-04-01","conditions":"Pancreas Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma","enrollment":40},{"nctId":"NCT03088540","phase":"PHASE3","title":"Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-05-29","conditions":"Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma","enrollment":712},{"nctId":"NCT07403435","phase":"PHASE2","title":"Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-02-15","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":22},{"nctId":"NCT06964568","phase":"PHASE3","title":"CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-01","conditions":"Esophageal Carcinoma, Radiotherapy, Immunotherapy","enrollment":452},{"nctId":"NCT07378306","phase":"PHASE2","title":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT07371611","phase":"PHASE3","title":"Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Qunxing Li,MD","startDate":"2026-01-01","conditions":"Locally Advanced Oral Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma (OSCC)","enrollment":104},{"nctId":"NCT07370337","phase":"PHASE2","title":"Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-05-12","conditions":"Squamous Cell Carcinoma of External Auditory Canal, Locally Advanced Tumor","enrollment":50},{"nctId":"NCT05978193","phase":"PHASE2","title":"Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2023-01-01","conditions":"Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Metastatic Esophageal Squamous Cell Carcinoma","enrollment":100},{"nctId":"NCT07337096","phase":"NA","title":"Electro-Acupuncture in Lung cancER : EALER Study","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2026-01","conditions":"Non Small Cell Lung Cancer, Accupuncture, PD-1 Inhibitors","enrollment":424},{"nctId":"NCT05522985","phase":"PHASE2","title":"Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-11-07","conditions":"Head and Neck Squamous Cell Carcinoma, Neoadjuvant Chemotherapy","enrollment":122},{"nctId":"NCT03768414","phase":"PHASE3","title":"Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2019-02-07","conditions":"Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8","enrollment":452},{"nctId":"NCT06676449","phase":"PHASE3","title":"TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-11-01","conditions":"Esophageal Carcinoma, Radiotherapy, Immunotherapy","enrollment":432},{"nctId":"NCT07139951","phase":"PHASE2","title":"Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for the Treatment of Patients With Gastric and Gastroesophageal Junction Adenocarcinoma at High Risk of Peritoneal Recurrence","status":"ENROLLING_BY_INVITATION","sponsor":"Mayo Clinic","startDate":"2025-12-03","conditions":"Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8","enrollment":16},{"nctId":"NCT07310771","phase":"PHASE2","title":"Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2026-01-10","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-SCCHN)","enrollment":23},{"nctId":"NCT02270814","phase":"PHASE2","title":"Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2015-02-02","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Head and Neck","enrollment":74},{"nctId":"NCT04004871","phase":"PHASE2","title":"Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Guangxi Medical University","startDate":"2019-03-28","conditions":"Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharynx Cancer","enrollment":60},{"nctId":"NCT06783140","phase":"PHASE2, PHASE3","title":"Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-06-10","conditions":"Pancreatic Cancer, Advanced or Metastatic, BRCA1/2 Mutation, PALB2 Gene Mutation","enrollment":10},{"nctId":"NCT04974047","phase":"PHASE2","title":"Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2021-08-17","conditions":"Resectable Esophageal Squamous Cell Carcinoma","enrollment":70},{"nctId":"NCT07251582","phase":"PHASE3","title":"Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2025-12-07","conditions":"Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)","enrollment":156},{"nctId":"NCT07251062","phase":"PHASE2, PHASE3","title":"A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-12-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":737},{"nctId":"NCT07086469","phase":"PHASE2","title":"Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-20","conditions":"Toripalimab, Surufatinib, Neoadjuvant Immunochemotherapy","enrollment":69},{"nctId":"NCT06010303","phase":"PHASE2","title":"A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-11-08","conditions":"Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma by AJCC V8 Stage","enrollment":118},{"nctId":"NCT04623775","phase":"PHASE2","title":"A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-02-17","conditions":"Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer","enrollment":468},{"nctId":"NCT06869213","phase":"PHASE2","title":"A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-03-31","conditions":"Esophageal Cancer (EsC)","enrollment":30},{"nctId":"NCT06869226","phase":"PHASE2","title":"A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-04-30","conditions":"Esophageal Cancer","enrollment":283},{"nctId":"NCT05775796","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2023-03-15","conditions":"Non-small Cell Lung Cancer, Stage II-IIIA, Immunotherapy","enrollment":30},{"nctId":"NCT05020457","phase":"PHASE2","title":"SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2021-12-07","conditions":"Non Small Cell Lung Cancer","enrollment":69},{"nctId":"NCT06143748","phase":"PHASE2","title":"Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-02","conditions":"Esophagus Cancer","enrollment":46},{"nctId":"NCT06601309","phase":"PHASE2","title":"Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2024-07-11","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":90},{"nctId":"NCT04126525","phase":"PHASE2","title":"Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"RenJi Hospital","startDate":"2019-06-18","conditions":"Breast Cancer Female","enrollment":53},{"nctId":"NCT07055399","phase":"PHASE2","title":"Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)","status":"RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-08-21","conditions":"Locally Advanced Cervical Cancer","enrollment":43},{"nctId":"NCT06831136","phase":"PHASE2","title":"Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2025-03-26","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":24},{"nctId":"NCT07153952","phase":"PHASE1, PHASE2","title":"RT for Adenocarcinoma/Adenosquamous Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-01-01","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Radiotherapy","enrollment":60},{"nctId":"NCT05880082","phase":"PHASE2","title":"PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer","status":"COMPLETED","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2023-01-13","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":118},{"nctId":"NCT07137039","phase":"PHASE2","title":"Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-08-20","conditions":"Locally Advanced Hypopharyngeal Cancer","enrollment":34},{"nctId":"NCT02327078","phase":"PHASE1, PHASE2","title":"A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2014-11-26","conditions":"B-cell Malignancies, Colorectal Cancer (CRC), Head and Neck Cancer","enrollment":307},{"nctId":"NCT07115095","phase":"NA","title":"Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer","status":"COMPLETED","sponsor":"Nanlin Li","startDate":"2021-01-01","conditions":"HER2-positive Breast Cancer","enrollment":98},{"nctId":"NCT00716417","phase":"PHASE1","title":"Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-07-01","conditions":"Neoplasms","enrollment":47},{"nctId":"NCT06423326","phase":"PHASE2","title":"Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2024-08-06","conditions":"Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8","enrollment":36},{"nctId":"NCT07088484","phase":"","title":"Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-08-01","conditions":"Recurrent Nasopharyngeal Carcinoma","enrollment":50},{"nctId":"NCT05834543","phase":"PHASE1, PHASE2","title":"Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-05-26","conditions":"Advanced Esophageal Squamous Cell Carcinoma","enrollment":34},{"nctId":"NCT07055841","phase":"PHASE2","title":"Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Xiuping Ding","startDate":"2023-04-01","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":69},{"nctId":"NCT05272696","phase":"PHASE2","title":"Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2022-03-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":86},{"nctId":"NCT07035808","phase":"PHASE2","title":"a Single Arm, Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Patients With Advanced Cervical Cancer .","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-07-01","conditions":"Cervical Cancer Stage IVA, Cervical Cancer Metastatic","enrollment":46},{"nctId":"NCT07034742","phase":"EARLY_PHASE1","title":"Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-06-01","conditions":"Gastric Adenocarcinoma","enrollment":136},{"nctId":"NCT04634877","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-01-10","conditions":"Endometrial Neoplasms","enrollment":990},{"nctId":"NCT06446726","phase":"PHASE2","title":"Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-06-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT06277791","phase":"PHASE2","title":"The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Hospital of Stomatology, Wuhan University","startDate":"2023-08-19","conditions":"Clinical IVb Stage Oral Squamous Cell Carcinomas Patients","enrollment":35},{"nctId":"NCT04990609","phase":"PHASE2","title":"EUS-RFA PANCARDINAL-1 Trial","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-08-13","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":60},{"nctId":"NCT06978829","phase":"PHASE2","title":"Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2025-03-01","conditions":"LA HNSCC","enrollment":42},{"nctId":"NCT03201861","phase":"PHASE3","title":"Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2017-07-27","conditions":"Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Duct Carcinoma of Breast","enrollment":762},{"nctId":"NCT06963593","phase":"PHASE4","title":"Clinical Study on the Treatment of Anorexia and Cachexia in Advanced Gastric and Esophageal Cancer With Nanosized Megestrol Acetate Combined With Immunochemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2025-06-01","conditions":"Advanced Gastroesophageal Cancer","enrollment":220},{"nctId":"NCT06944587","phase":"","title":"A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-12-03","conditions":"Locally Advanced Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Pancreatectomy","enrollment":400},{"nctId":"NCT06942416","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-02-28","conditions":"Cervical Cancer, Neoplasm Recurrence, Local, Oligometastatic","enrollment":36},{"nctId":"NCT05179239","phase":"PHASE3","title":"A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer","status":"TERMINATED","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2022-02-26","conditions":"Cervical Cancer","enrollment":31},{"nctId":"NCT04793932","phase":"PHASE3","title":"Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Associazione Italiana per lo Studio del Pancreas","startDate":"2020-11-03","conditions":"Pancreas Ductal Adenocarcinoma","enrollment":261},{"nctId":"NCT06916117","phase":"PHASE2","title":"Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-04-05","conditions":"Locally Advanced Cervical Cancer","enrollment":30},{"nctId":"NCT06904573","phase":"PHASE2","title":"Probiotics in Advanced Urothelial Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-01-01","conditions":"Advanced Urothelial Carcinoma, Probiotics, Immunotherapy","enrollment":222},{"nctId":"NCT06895369","phase":"PHASE2","title":"The Efficacy and Safety of Pucotenlimab Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced HNSCC","status":"NOT_YET_RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2025-05-01","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":30},{"nctId":"NCT06258811","phase":"PHASE3","title":"Neoadjuvant Immunochemotherapy for LAOSCC","status":"RECRUITING","sponsor":"Lai-ping Zhong","startDate":"2024-02-20","conditions":"Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma","enrollment":134},{"nctId":"NCT05932212","phase":"PHASE2","title":"AK104 for Recurrent or Metastatic Vulvar Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2023-08-25","conditions":"Vulvar Cancer","enrollment":20},{"nctId":"NCT06861777","phase":"PHASE2, PHASE3","title":"Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC","status":"NOT_YET_RECRUITING","sponsor":"YIN LI","startDate":"2025-03","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":474},{"nctId":"NCT06863831","phase":"NA","title":"A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC","status":"ENROLLING_BY_INVITATION","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-08-22","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":536},{"nctId":"NCT04460352","phase":"PHASE3","title":"Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer","status":"RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2020-11-27","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":1020},{"nctId":"NCT04868708","phase":"PHASE2","title":"A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer","status":"COMPLETED","sponsor":"Akeso","startDate":"2021-04-01","conditions":"Recurrent or Metastatic Cervical Cancer","enrollment":50},{"nctId":"NCT06494943","phase":"PHASE1, PHASE2","title":"Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-06-26","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma","enrollment":27},{"nctId":"NCT06814158","phase":"PHASE2","title":"Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-03-01","conditions":"Esophageal Squamour Cell Cancer","enrollment":57},{"nctId":"NCT03099135","phase":"PHASE3","title":"A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-04-10","conditions":"Hepatitis C","enrollment":24},{"nctId":"NCT06197776","phase":"","title":"Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-07-15","conditions":"Multi-omics Technique, Nasopharyngeal Carcinoma, Recurrent and Metastatic Nasopharyngeal Carcinoma","enrollment":50},{"nctId":"NCT04544969","phase":"","title":"Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-04-01","conditions":"Circulating Tumor Cell, Nasopharyngeal Carcinoma, Distant Metastases.Clinical","enrollment":50},{"nctId":"NCT06781112","phase":"PHASE2","title":"A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Weiwei Zhang","startDate":"2025-01-20","conditions":"TPF, Immunotherapy, Nasopharyngeal Carcinoma","enrollment":35},{"nctId":"NCT06781073","phase":"PHASE3","title":"Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma","status":"COMPLETED","sponsor":"Biotech Pharmaceutical Co., Ltd.","startDate":"2017-07-06","conditions":"Cervical Squamous Cell Carcinoma, Persistent","enrollment":118},{"nctId":"NCT06669611","phase":"PHASE3","title":"Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-27","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":242},{"nctId":"NCT05214222","phase":"PHASE2","title":"Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2022-09-02","conditions":"Advanced Esophageal Squamous Cell Carcinoma","enrollment":100},{"nctId":"NCT06746870","phase":"PHASE2","title":"A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","startDate":"2024-12","conditions":"NSCLC, TNBC","enrollment":148},{"nctId":"NCT06718309","phase":"PHASE2","title":"Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC","status":"RECRUITING","sponsor":"First People's Hospital of Hangzhou","startDate":"2024-04-24","conditions":"Non-Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT06714084","phase":"NA","title":"CNCMT：a Multi-center, Prospective, Single-arm Study","status":"ENROLLING_BY_INVITATION","sponsor":"Hubei Cancer Hospital","startDate":"2024-10-08","conditions":"Locally Advanced Cervical Cancer, PD1, CTLA4","enrollment":20},{"nctId":"NCT06713057","phase":"PHASE2","title":"Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2024-12-01","conditions":"Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer","enrollment":20},{"nctId":"NCT06714266","phase":"PHASE2","title":"Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2024-12-15","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":30},{"nctId":"NCT06444009","phase":"PHASE2","title":"A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Lei Liu","startDate":"2024-07-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":90},{"nctId":"NCT06703047","phase":"PHASE2","title":"Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-11-20","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":180},{"nctId":"NCT05979818","phase":"PHASE1","title":"Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2024-11-13","conditions":"Non Small Cell Lung Cancer, Propranolol","enrollment":6},{"nctId":"NCT05520619","phase":"PHASE2","title":"Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-09-15","conditions":"Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma","enrollment":114},{"nctId":"NCT06690476","phase":"EARLY_PHASE1","title":"Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Peking University","startDate":"2024-10-10","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":74},{"nctId":"NCT06664983","phase":"PHASE3","title":"TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-10-21","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":84},{"nctId":"NCT06663059","phase":"PHASE2","title":"Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-10-01","conditions":"Esophageal Cancer","enrollment":80},{"nctId":"NCT03432598","phase":"PHASE2","title":"Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2017-08-24","conditions":"Locally Advanced Lung Cancer; Metastatic Lung Cancer","enrollment":54},{"nctId":"NCT06649448","phase":"NA","title":"A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2024-10-10","conditions":"Solid Tumor Cancer, Chemotherapy Induced Neutropenia, G-CSF","enrollment":200},{"nctId":"NCT04664972","phase":"PHASE2","title":"Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2018-11-23","conditions":"Triple Negative Breast Cancer","enrollment":212},{"nctId":"NCT06588335","phase":"PHASE2","title":"BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Henan Provincial People's Hospital","startDate":"2024-09-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Docetaxel, Cisplatin","Paclitaxel/Platinum"],"phase":"phase_3","status":"active","brandName":"TP regimen","genericName":"TP regimen","companyName":"Tianjin Medical University Cancer Institute and Hospital","companyId":"tianjin-medical-university-cancer-institute-and-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TP regimen is a chemotherapy combination of docetaxel (Taxotere) and cisplatin that disrupts microtubule dynamics and DNA replication to kill cancer cells. Used for Non-small cell lung cancer, Gastric cancer, Head and neck cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}